AbbVie presents 22 IBD abstracts and AbbVie stock costs EUR 247.55
Published on 10/12/2026 at 12:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- AbbVie announced 22 inflammatory bowel disease abstracts for the ACG 2026 meeting on October 11, 2026.
- RINVOQ data showed 93.30 percent clinical and steroid-free remission among fistulizing disease patients who remained on treatment.
- AbbVie reported second-quarter 2026 revenue of USD 16.99 billion, up 10.20 percent year over year, and adjusted earnings per share of USD 3.65.
- The stock was at EUR 247.55 at Lang & Schwarz on October 12, 2026, plus 0.75 percent versus the Xetra close of EUR 245.70 on October 9, 2026.
AbbVie Inc. (ISIN US00287Y1091) announced 22 inflammatory bowel disease abstracts on October 11, 2026, while AbbVie stock was trading at EUR 247.55 at Lang & Schwarz on October 12, 2026. The current program highlights SKYRIZI and RINVOQ data at the American College of Gastroenterology meeting, giving the immunology portfolio a fresh clinical focus.
ACG data add a fresh catalyst
According to PR Newswire on October 11, 2026, the presentation includes Phase 3 AFFIRM results for SKYRIZI, long-term extension data and real-world RINVOQ evidence. In the cited RINVOQ study, 93.30 percent of patients with fistulizing disease who remained on treatment achieved clinical remission and corticosteroid-free remission.
The program also includes six-month data in which 57.00 percent of patients with isolated ileal disease achieved clinical remission, while 58.00 percent achieved endoscopic response. Those figures give the event a measurable operating angle: AbbVie is presenting both controlled trial evidence and treatment outcomes from routine care.
What does the evidence add?
AbbVie enters the meeting with a sizeable recent earnings base. MarketBeat reported on October 9, 2026, that second-quarter 2026 revenue rose 10.20 percent year over year to USD 16.99 billion and adjusted earnings per share reached USD 3.65 versus a USD 3.61 consensus estimate.
The market is also weighing execution against pipeline spending. MarketBeat said on October 9, 2026, that Guggenheim reaffirmed a Buy rating and set a USD 288.00 price target. The target remains a separate US dollar reference and is not combined with the euro quotation.
AbbVie chronology carries three figures
On September 3, 2026, AbbVie completed its Apogee Therapeutics acquisition for USD 10.9 billion, according to Ticker Scout. On October 5, 2026, an SEC filing showed a USD 216 million pre-tax acquired research and development and milestones expense. On October 11, 2026, AbbVie announced 22 IBD abstracts through PR Newswire.
Next dates include October 30
According to Trivano on October 1, 2026, AbbVie will announce third-quarter 2026 results on October 30, 2026, before the US market opens, followed by an earnings call at 8:00 a.m. Central time. The ACG meeting runs through October 14, 2026, with additional SKYRIZI and RINVOQ presentations scheduled during the event.
Stock holds above the Xetra close
AbbVie stock was trading at EUR 247.55 at Lang & Schwarz on October 12, 2026 at 12:37 p.m. CEST, up EUR 1.85 or 0.75 percent versus the Xetra close of EUR 245.70 on October 9, 2026. The current euro quotation sits alongside a USD 488.5 billion market capitalization from the latest US listing data.
The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock facts on October 12, 2026
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 12, 2026, 12:37 p.m. CEST): EUR 247.55
- Change versus Xetra close: plus 0.75 percent
- Xetra close (October 9, 2026): EUR 245.70
- Market capitalization: USD 488.5 billion (as of October 9, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 30, 2026
Market context: Market report S&P 500.
